Showing results (371-380 of 389) with videos related to

Sort By:
Pageof 39
Molecular & Cellular Proteomics : MCP|January 14, 2023
TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery From DNA DamagePhilamer C Calses, Victoria C Pham, Alissa D Guarnaccia, et al.
Translational Lung Cancer Research|January 13, 2023
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohortZihua Zou, Yangchun Gu, Li Liang, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Thoracic Cancer|May 31, 2019
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Xia Song, Yuhui Zhang, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.
Frontiers in Immunology|July 18, 2022
Long-Term Prognostic Factors in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A 15-Year Multicenter Retrospective StudyQian-Qian Liao, Ya-Fei Ren, Ke-Wei Zhu, et al.
Thoracic Cancer|December 22, 2021
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in ChinaYuequan Shi, Jian Fang, Chengzhi Zhou, et al.
Science Advances|November 25, 2015
Habitat fragmentation and its lasting impact on Earth's ecosystemsNick M Haddad, Lars A Brudvig, Jean Clobert, et al.
Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.
Pageof 39